In Depth Research on Global HIV Vaccine Market Future Outlook

"Global HIV Vaccine Market Future Outlook" Report Highlights:

* Introduction to HIV Vaccines
* Issues Related to the Development of HIV Vaccines
* Parameters for Successful Commercialization of HIV Vaccines
* Global HIV Vaccines Market Opportunity Analysis
* Global HIV Vaccine Clinical Pipeline by Company & Phase
* Global HIV Vaccine Clinical Pipeline: 100 Vaccines
* Majority Vaccine in Preclinical Phase: 42 Vaccines

For Report Sample Contact: neeraj@kuickresearch.com

Report Weblink:https://www.kuickresearch.com/report-Global-HIV-Vaccine-Market-Future-Outlook.php

Table of Contents

1. Introduction to HIV Vaccines

2. Issues Related to the Development of HIV Vaccines
2.1 Lack of Antigenicity
2.2 HIV Polymorphism
2.3 High Mutation Rates
2.4 Compromised Immune System
2.5 Integration with DNA

3. Parameters for Successful Commercialization of HIV Vaccines
3.1 Long Term Efficacy
3.2 Reduced Transmission
3.3 Relapse Prevention
3.4 Cost Effectiveness
3.5 Manufacturing Scalability

4. Mechanism of HIV Vaccines

5. Global HIV Vaccines Market Opportunity Analysis
5.1 Market Overview
5.2 HIV Vaccine Clinical Pipeline Overview

6. Global HIV Incidence Rates

7. Global HIV Vaccine Market Dynamics
7.1 Funding Scenario for HIV Vaccine
7.2 Favorable Market Parameters
7.3 HIV Vaccines Commercialization Challenges

8. Global HIV Vaccines Market Future Prospects

9. Global HIV Vaccine Clinical Pipeline by Company & Phase
9.1 Research
9.2 Preclinical
9.3 Clinical
9.4 Phase-I
9.5 Phase-I/II
9.6 Phase-II
9.7 Phase-III
9.8 Preregistration

10. Discontinued & Suspended HIV Vaccines in Clinical Pipeline by Company & Phase
10.1 Discontinued
10.2 Suspended
10.3 No Development Reported

11. Competitive Landscape
11.1 AlphaVax
11.2 Antigen Express
11.3 Argo Therapeutics
11.4 Bionor Pharmaceuticals
11.5 Celldex Therapeutics
11.6 FIT Biotech
11.7 Crucell Pharmaceutical
11.8 GeneCure
11.9 Genetic Immunity
11.10 GenVec
11.11 GeoVax Labs
11.12 Glaxo Smithkline
11.13 Immune Response BioPharma
11.14 Inovio Pharmaceuticals
11.15 Novartis
11.16 Oncolys Biopharma
11.17 PaxVax
11.18 Profectus Biosciences
11.19 Sanofi
11.20 TVAX Biomedical

Figure 1-1: Effects of HIV Disease
Figure 1-2: Methods of HIV Transmission
Figure 1-3: Modalities to Treat HIV Infection
Figure 2-1: Issues Related to the Development of HIV Vaccines
Figure 3-1: Requirements for Successful Commercialization of HIV Vaccines
Figure 4-1: Types of HIV Vaccines
Figure 4-2: Techniques to Develop HIV Vaccines
Figure 4-3: Mechanism of SAV001 Vaccine
Figure 4-4: Mechanism of AIDSVAX HIV Vaccine
Figure 4-5: Mechanism of V520 HIV Vaccine
Figure 5-1: HIV Vaccine Clinical Pipeline by Phase (%), 2015
Figure 5-2: HIV Vaccine Clinical Pipeline by Phase (Number), 2015
Figure 5-3: No Development Reported HIV Vaccine Clinical Pipeline by Phase (%), 2015
Figure 5-4: No Development Reported HIV Vaccine Clinical Pipeline by Phase (Number), 2015
Figure 5-5: Discontinued HIV Vaccine Clinical Pipeline by Phase (%), 2015
Figure 5-6: Discontinued HIV Vaccine Clinical Pipeline by Phase (Number), 2015
Figure 6-1: People Living With HIV Infection (Million), 2009-2014
Figure 6-2: New Incidence of HIV Infection (Million), 2009-2012
Figure 7-1: Global HIV Vaccines R&D Funding (US$ Million), 2005–2012
Figure 7-2: Global HIV Vaccines R&D Funding Breakup (%), 2012
Figure 7-3: Philanthropic Sector Spending on HIV Vaccines by Clinical Research Phase (%), 2012
Figure 7-4: HIV Vaccine Market Favorable Parameters
Figure 7-5: HIV Vaccines Commercialization Challenges
Figure 8-1: Estimated HIV Market Size with Routine Vaccination Only
Figure 11-1: AlphaVax Clinical Pipeline
Figure 11-2: Bionor Pharma Clinical Pipeline
Figure 11-3: TVAX Biomedical Clinical Pipeline

Table 4-1: HIV Vaccine Antigens under Investigation
Table 6-1: Comparative Analysis of HIV Associated Features across the Globe
Table 7-1: HIV Vaccines Funding by Sector (US$ Million), 2006-2012
Table 8-1: Global Impact of a Vaccine on AIDS Incidence and Mortality

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
India
+91-11-47067990

This release was published on openPR.